TRAIL activates acid sphingomyelinase via a redox mechanism and releases ceramide to trigger apoptosis

被引:130
作者
Dumitru, C. A. [1 ]
Gulbins, E. [1 ]
机构
[1] Univ Duisburg Essen, Dept Mol Biol, D-45122 Essen, Germany
关键词
ceramide; acid sphingomyelinase; TRAIL; apoptosis; tumor therapy; redox;
D O I
10.1038/sj.onc.1209568
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We have previously shown that activation of the acid sphingomyelinase (ASM), the release of ceramide and the formation of ceramide-enriched membrane domains are central for the induction of apoptosis by CD95. Here, we demonstrate that tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and CD95 activate the ASM via a redox mechanism resulting in release of ceramide and formation of ceramide-enriched membrane platforms. Ceramide-enriched membrane platforms serve to cluster DR5 upon stimulation. Antioxidants prevent TRAIL-mediated stimulation of ASM, the release of ceramide, the formation of ceramide-enriched membrane platforms and the induction of apoptosis by TRAIL. Further, ASM-deficient splenocytes fail to cluster DR5 in ceramide-enriched membrane domains upon TRAIL stimulation and resist TRAIL-induced apoptosis, events that were restored by addition of natural C-16-ceramide. A dose-response analysis indicates that ceramide-enriched membrane platforms greatly sensitized tumor cells to TRAIL-induced apoptosis. Our data indicate that ceramide-enriched membrane platforms are required for the signaling of TRAIL-DR5 complexes under physiological conditions.
引用
收藏
页码:5612 / 5625
页数:14
相关论文
共 68 条
[1]   L-carnitine prevents doxorubicin-induced apoptosis of cardiac myocytes:: role of inhibition of ceramide generation [J].
Andrieu-Abadie, N ;
Jaffrézou, JP ;
Hatem, S ;
Laurent, G ;
Levade, T ;
Mercadier, JJ .
FASEB JOURNAL, 1999, 13 (12) :1501-1510
[2]   Caspase-3 is a component of fas death-inducing signaling complex in lipid rafts and its activity is required for complete caspase-8 activation during Fas-mediated cell death [J].
Aouad, SM ;
Cohen, LY ;
Sharif-Askari, E ;
Haddad, EK ;
Alam, A ;
Sekaly, RP .
JOURNAL OF IMMUNOLOGY, 2004, 172 (04) :2316-2323
[3]   Safety and antitumor activity of recombinant soluble Apo2 ligand [J].
Ashkenazi, A ;
Pai, RC ;
Fong, S ;
Leung, S ;
Lawrence, DA ;
Masters, SA ;
Blackie, C ;
Chang, L ;
McMurtrey, AE ;
Hebert, A ;
DeForge, L ;
Koumenis, IL ;
Lewis, D ;
Harris, L ;
Bussiere, J ;
Koeppen, H ;
Shahrokh, Z ;
Schwall, RH .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (02) :155-162
[4]   Apoptosis-modulating agents in combination with radiotherapy-current status and outlook [J].
Belka, C ;
Jendrossek, V ;
Pruschy, M ;
Vink, S ;
Verheij, M ;
Budach, W .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 58 (02) :542-554
[5]   The tyrosine kinase Lck is required for CD95-independent caspase-8 activation and apoptosis in response to ionizing radiation [J].
Belka, C ;
Marini, P ;
Lepple-Wienhues, A ;
Budach, W ;
Jekle, A ;
Los, M ;
Lang, F ;
Schulze-Osthoff, K ;
Gulbins, E ;
Bamberg, M .
ONCOGENE, 1999, 18 (35) :4983-4992
[6]   Sensitization of resistant lymphoma cells to irradiation-induced apoptosis by the death ligand TRAIL [J].
Belka, C ;
Schmid, B ;
Marini, P ;
Durand, E ;
Rudner, J ;
Faltin, H ;
Bamberg, M ;
Schulze-Osthoff, K ;
Budach, W .
ONCOGENE, 2001, 20 (17) :2190-2196
[7]   Receptor-mediated choreography of life and death [J].
Bhardwaj, A ;
Aggarwal, BB .
JOURNAL OF CLINICAL IMMUNOLOGY, 2003, 23 (05) :317-332
[8]   The transmembranous domain of CD40 determines CD40 partitioning into lipid rafts [J].
Bock, J ;
Gulbins, E .
FEBS LETTERS, 2003, 534 (1-3) :169-174
[9]   Initiation of signal transduction through the T cell receptor requires the peptide multivalent engagement of MHC ligands [J].
Boniface, JJ ;
Rabinowitz, JD ;
Wülfing, C ;
Hampl, J ;
Reich, Z ;
Altman, JD ;
Kantor, RM ;
Beeson, C ;
McConnell, HM ;
Davis, MM .
IMMUNITY, 1998, 9 (04) :459-466
[10]   Structure and origin of ordered lipid domains in biological membranes [J].
Brown, DA ;
London, E .
JOURNAL OF MEMBRANE BIOLOGY, 1998, 164 (02) :103-114